Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Official Title
NIDA-CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Quick Facts
Study Start:2021-06-08
Study Completion:2026-12-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
Little Rock, Arkansas, 72205
United States
Tarzana Treatment Centers, Inc.
Tarzana, California, 91356
United States
Liberation Programs, Inc.
Bridgeport, Connecticut, 06610
United States
Operation PAR
Clearwater, Florida, 33760
United States
Gateway Community Services
Jacksonville, Florida, 32204
United States
Aspire Health Partners
Orlando, Florida, 32806
United States
Mountain Manor / Maryland Treatment Centers
Baltimore, Maryland, 21229
United States
McLean Hospital
Belmont, Massachusetts, 02478
United States
Stanley Street Treatment and Resources, Inc.
Fall River, Massachusetts, 02720
United States
Square Medical Group, LLC
Newton, Massachusetts, 02458
United States
Gibson Center for Behavioral Change
Cape Girardeau, Missouri, 63703
United States
Dartmouth Hitchcock - ATP
Lebanon, New Hampshire, 03766
United States
University of New Mexico Addiction and Substance Abuse Program
Albuquerque, New Mexico, 87106
United States
Bellevue Hospital Center
New York, New York, 10016
United States
Adapt Integrated Health Care
Roseburg, Oregon, 97470
United States
Adapt Integrated Health Care
Winston, Oregon, 97496
United States
Center for Psychiatric and Chemical Dependency Services (CPCDS)
Pittsburgh, Pennsylvania, 15213
United States
Internal Medicine Recovery Engagement Program (IM-REP)
Pittsburgh, Pennsylvania, 15219
United States
Shoreline Behavioral Health Services
Conway, South Carolina, 29526
United States
Huntsman Mental Health Institute / University of Utah
Salt Lake City, Utah, 84108
United States
Chestnut Ridge Center
Morgantown, West Virginia, 26505
United States
Collaborators and Investigators
Sponsor: NYU Langone Health
- Edward V Nunes, MD, PRINCIPAL_INVESTIGATOR, New York State Psychiatric Institute/Columbia University Irving Medical Center
- John Rotrosen, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health
- Roger Weiss, MD, PRINCIPAL_INVESTIGATOR, Harvard Medical School/McLean Hospital
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2021-06-08
Study Completion Date2026-12-28
Study Record Updates
Study Start Date2021-06-08
Study Completion Date2026-12-28
Terms related to this study
Additional Relevant MeSH Terms
- Opioid Use Disorder (OUD)